Financial Performance - TransAct Technologies Incorporated (TACT) reported break-even quarterly earnings per share, compared to a Zacks Consensus Estimate of a loss of $0.10, marking an earnings surprise of 100% [1] - The company posted revenues of $13.05 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 19.21%, compared to year-ago revenues of $10.69 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Performance - TransAct Technologies shares have lost about 17.1% since the beginning of the year, while the S&P 500 has declined by only 0.6% [3] - The current status of estimate revisions translates into a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the coming quarter is -$0.08 on $11.65 million in revenues, and -$0.26 on $48 million in revenues for the current fiscal year [7] - The outlook for the industry, specifically the Computer - Peripheral Equipment sector, is currently in the bottom 15% of the Zacks industries, which may impact the stock's performance [8]

Group 1 - Hyliion Holdings Corp. reported a quarterly loss of $0.10 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.08, marking a 25% earnings surprise [1] - The company generated revenues of $0.49 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 55.55%, compared to zero revenues a year ago [2] - Hyliion shares have declined approximately 31.4% since the beginning of the year, contrasting with the S&P 500's decline of only 0.6% [3] Group 2 - The earnings outlook for Hyliion is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.09 on revenues of $1.15 million, and -$0.30 on revenues of $12.45 million for the current fiscal year [7] - The Zacks Industry Rank places the Automotive - Original Equipment sector in the bottom 36% of over 250 Zacks industries, indicating potential challenges for stock performance [8] Group 3 - The estimate revisions trend for Hyliion is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Webtoon Entertainment (WBTN) reported quarterly earnings of $0.03 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, but down from $1.73 per share a year ago [1] - The earnings surprise was 50%, and the company has surpassed consensus EPS estimates in all four of the last quarters [2] - Revenues for the quarter were $325.71 million, slightly above the Zacks Consensus Estimate by 0.53%, but down from $326.74 million year-over-year [3] Financial Performance - The company has consistently outperformed consensus revenue estimates three times in the last four quarters [3] - The current consensus EPS estimate for the upcoming quarter is $0.06, with expected revenues of $337.87 million, and for the current fiscal year, the EPS estimate is $0.31 on revenues of $1.43 billion [8] Market Position - Webtoon shares have declined approximately 29.7% since the beginning of the year, contrasting with the S&P 500's decline of 0.6% [4] - The Zacks Industry Rank places the Internet - Software sector in the top 36% of over 250 Zacks industries, indicating a favorable position compared to the bottom 50% [9] Future Outlook - The estimate revisions trend for Webtoon is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market [7] - The upcoming earnings call will be crucial for understanding management's commentary and future earnings expectations [4]

Company Performance - Verb Technology Company, Inc. reported a quarterly loss of $2.51 per share, which was better than the Zacks Consensus Estimate of a loss of $3.14, and a significant improvement from a loss of $22 per share a year ago, indicating an earnings surprise of 20.06% [1] - The company posted revenues of $1.31 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 63.13%, compared to revenues of $0.01 million in the same quarter last year [2] - Over the last four quarters, Verb Technology has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Outlook - Verb Technology shares have declined approximately 11.2% since the beginning of the year, while the S&P 500 has only declined by 0.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$2.97 on revenues of $0.9 million, and for the current fiscal year, it is -$11.25 on revenues of $3.4 million [7] - The estimate revisions trend for Verb Technology is currently unfavorable, resulting in a Zacks Rank 5 (Strong Sell), indicating expected underperformance in the near future [6] Industry Context - The Internet - Software industry, to which Verb Technology belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting that companies in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]

Core Insights - Camtek (CAMT) reported quarterly earnings of $0.79 per share, exceeding the Zacks Consensus Estimate of $0.77 per share, and up from $0.63 per share a year ago [1][2] - The company posted revenues of $118.64 million for the quarter, slightly missing the Zacks Consensus Estimate by 0.30%, but up from $97.01 million year-over-year [3] - The stock has underperformed the market, losing about 14.3% since the beginning of the year compared to the S&P 500's decline of -0.6% [4] Earnings Performance - The earnings surprise for the recent quarter was 2.60%, and the company has surpassed consensus EPS estimates in all four of the last quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.78, with expected revenues of $120.85 million, and for the current fiscal year, the estimate is $3.16 on revenues of $485.55 million [8] Industry Context - Camtek operates within the Zacks Electronics - Measuring Instruments industry, which is currently ranked in the bottom 10% of over 250 Zacks industries [9] - The industry outlook can significantly impact stock performance, with research indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [9] Future Outlook - The estimate revisions trend for Camtek is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [7] - The upcoming earnings call will be crucial for assessing future earnings expectations and management's commentary [4][5]

Financial Performance - Broadwind Energy reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of a loss of $0.03, and compared to earnings of $0.07 per share a year ago, indicating an earnings surprise of 33.33% [1] - The company posted revenues of $36.84 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 8.56%, although this represents a decline from year-ago revenues of $37.62 million [2] Stock Performance - Broadwind Energy shares have declined approximately 14.4% since the beginning of the year, contrasting with the S&P 500's decline of only 0.6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.06 on revenues of $39.55 million, and for the current fiscal year, it is $0.07 on revenues of $152.66 million [7] Industry Outlook - The Manufacturing - General Industrial industry, to which Broadwind Energy belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, suggesting potential challenges ahead [8]

WhiteHorse Finance (WHF) came out with quarterly earnings of $0.29 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.47 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.12%. A quarter ago, it was expected that this lender to small companies would post earnings of $0.39 per share when it actually produced earnings of $0.34, delivering a surprise of -12.82%.Over the last four ...

Core Viewpoint - Sangamo Therapeutics reported a quarterly loss of $0.14 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.11, marking an earnings surprise of -27.27% [1] - The company generated revenues of $6.44 million for the quarter, missing the consensus estimate by 29.77%, compared to $0.48 million in the same quarter last year [2] Group 1: Financial Performance - The company has surpassed consensus EPS estimates only once in the last four quarters [2] - Sangamo shares have declined approximately 31.4% year-to-date, contrasting with the S&P 500's decline of -3.8% [3] Group 2: Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $14.8 million, and for the current fiscal year, it is -$0.39 on revenues of $46.97 million [7] - The estimate revisions trend for Sangamo is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Group 3: Industry Context - The Medical - Biomedical and Genetics industry is ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - OptimizeRx Corp. reported quarterly earnings of $0.08 per share, exceeding the Zacks Consensus Estimate of a loss of $0.11 per share, marking a significant earnings surprise of 172.73% [1] - The company has consistently surpassed consensus EPS estimates over the last four quarters [2] Financial Performance - For the quarter ended March 2025, OptimizeRx posted revenues of $21.93 million, which is a 15.86% increase compared to the Zacks Consensus Estimate and an increase from $19.69 million year-over-year [2] - The company has topped consensus revenue estimates two times in the last four quarters [2] Stock Performance - OptimizeRx shares have increased by approximately 105.6% since the beginning of the year, contrasting with a decline of 3.8% in the S&P 500 [3] - The stock's immediate price movement will depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $21.43 million, while for the current fiscal year, it is $0.40 on revenues of $101.98 million [7] - The estimate revisions trend for OptimizeRx is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Computer - Software industry, to which OptimizeRx belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook [8] - The top 50% of Zacks-ranked industries outperform the bottom 50% by more than a factor of 2 to 1 [8]

Core Viewpoint - Acadia Healthcare reported quarterly earnings of $0.40 per share, exceeding the Zacks Consensus Estimate of $0.35 per share, but down from $0.84 per share a year ago [1][2] Financial Performance - The company achieved revenues of $770.51 million for the quarter ended March 2025, aligning with the Zacks Consensus Estimate and showing a slight increase from $768.05 million year-over-year [3] - Acadia Healthcare has surpassed consensus EPS estimates three times over the last four quarters, but has only topped revenue estimates once in the same period [2][3] Stock Performance - The stock has declined approximately 39.9% since the beginning of the year, contrasting with the S&P 500's decline of 3.8% [4] - The current Zacks Rank for Acadia Healthcare is 4 (Sell), indicating expectations of underperformance in the near future [7] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.77 on revenues of $852.98 million, and for the current fiscal year, it is $2.68 on revenues of $3.33 billion [8] - The trend of estimate revisions for Acadia Healthcare has been unfavorable leading up to the earnings release [7] Industry Context - The Medical - Hospital industry, to which Acadia Healthcare belongs, is currently ranked in the top 40% of over 250 Zacks industries, suggesting a favorable environment compared to the bottom 50% [9]